Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet

Epilepsy Clinical Trial

Official title: Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet

Status Not yet recruiting

Clinical Trial Summary

Ketogenic diet therapies (KDTs) emphasize high fat and very low carbohydrate intake and help to control seizures in adults who fail to respond to medications. However, KDT use can lead to increased cholesterol levels in some adults with epilepsy (AWE). Treatments that can reverse elevations in cholesterol observed with long-term KDT use without compromising diet adherence and seizure control are needed. The proposed study will explore the feasibility and safety of diet modification and statin use to lower cholesterol in this population. Study findings will help guide doctors utilizing KDTs in adults with epilepsy on how to approach managing elevations in cholesterol.

Clinical Trial Description

The scientific premise of this proposal is that established or long-term (≥ 12 months) Modified Atkins diet (MAD) use in AWE influences atherosclerotic cardiovascular disease (ASCVD) risk and can be modified to reduce dyslipidemia when observed. Hence, the overarching goals of this proposal are to explore the safety and feasibility of dyslipidemia management strategies to reduce ASCVD risk in AWE on MAD without increasing seizure risk. This study will collect data before and after randomly assigned interventions to reduce LDL in AWE on long-term MAD recruited from patients receiving clinical care in the Johns Hopkins Adult Epilepsy Diet Center.

AWE with dyslipidemia on long-term MAD will be randomized 1:1 to either MAD modification (10% reduction of dietary energy from saturated fat, replaced with poly-unsaturated fat ) or moderate-intensity statin use (atorvastatin 10mg) for 12 weeks. ;

Related Conditions & MeSH terms

• Dyslipidemia
• Dyslipidemias
• Epilepsy

• NCT number: NCT06369571
• Study type: Interventional
• Source: Johns Hopkins University
• Contact: Tanya J McDonald, MD, PhD
• Phone: 4105022227
• Email: twill145@jhmi.edu
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: July 2024
• Completion date: December 2027